抗体
试剂盒
多肽
探针
蛋白
组织芯片
产品中心
Product Center
Research Grade Crenezumab
All
TD-HY235016_1.jpg
TD-HY235016_2.jpg
- Catalog： TD-HY235016
- Clonality： mAb
- Application： Research Grade Biosimilar
- Synonyms： MABT5102A,RG7412,CAS:1095207-05-8
-
规格：
1mg
-
价格：
¥询价
定制服务咨询
Research Grade Crenezumab
| Catalog No. | TD-HY235016 |
|---|---|
| Species reactivity | Human |
| Applications | Research Grade Biosimilar |
| Host species | Humanized |
| Isotype | IgG4-kappa |
| Expression system | Mammalian Cells |
| Clonality | Monoclonal |
| Target | AICD-57, A4, Beta-CTF, Protease nexin-II, Gamma-CTF(50), ABPP, S-APP-beta, APP, Abeta40, Abeta42, AID(59), Amyloid intracellular domain 59, AID(57), S-APP-alpha, Gamma-CTF(59), Beta-secretase C-terminal fragment, Amyloid-beta precursor protein, Amyloid precursor protein, Beta-APP42, PreA4, Alzheimer disease amyloid protein, APPI, PN-II, AICD-59, Alpha-secretase C-terminal fragment, Amyloid-beta A4 protein, Amyloid intracellular domain 57, CVAP, Amyloid intracellular domain 50, Beta-APP40, AD1, Cerebral vascular amyloid peptide, AID(50), Alpha-CTF, Gamma-CTF(57), AICD-50 |
| Endotoxin level | Please contact the lab for this information. |
| Purity | >95% purity as determined by SDS-PAGE. |
| Purification | Protein A/G, purified from cell culture supernatant. |
| Accession | P05067 |
| Form | Liquid |
| Storage buffer | 0.01M PBS,pH7.4. |
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| Alternate Names | MABT5102A,RG7412,CAS:1095207-05-8 |
| Background | Crenezumab (MABT 5102A; RG 7412) is a fully humanized anti-Aβ monoclonal antibody that binds multiple forms of Aβ, such as soluble, oligomeric and fibrillar, for use in Alzheimer's disease research. |
| Note | For research use only. Not for use in clinical or therapeutic applications. |
|
|
SEC-HPLC detection for Research Grade Crenezumab. |
|
|
SDS-PAGE for Research Grade Crenezumab. |